Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK

Authors:

Abstract
The aim was to determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active psoriatic arthritis (PsA) who are tumour necrosis factor inhibitor (TNFi) naïve and without concomitant moderate-to-severe psoriasis, and who have responded inadequately to conventional systemic disease-modifying anti-rheumatic drugs (csDMARDs).
Funding Information
  • Novartis Pharmaceuticals UK Limited

This publication has 22 references indexed in Scilit: